Top-News

Lannett News

Keine aktuellen Kursdaten verfügbar
WKN: A3D5YL
ISIN: US5160122009
US-Symbol: LCINQ
Typ: Aktie

Lannett News

02.05.23 - PR Newswire
LANNETT COMPANY, INC. FILES PREPACKAGED CHAPTER 11 CASES TO SIGNIFICANTLY STRENGTHEN FINANCIAL POSITION
LANNETT COMPANY, INC. FILES PREPACKAGED CHAPTER 11 CASES TO SIGNIFICANTLY STRENGTHEN FINANCIAL POSITION PR Newswire
01.05.23 - PR Newswire
Lannett Company, Inc. Enters Into Restructuring Support Agreement
Lannett Company, Inc. Enters Into Restructuring Support Agreement PR Newswire
20.04.23 - PR Newswire
NYSE TO SUSPEND TRADING IMMEDIATELY IN LANNETT COMPANY, INC. (LCI) AND COMMENCE DELISTING PROCEEDINGS
NYSE TO SUSPEND TRADING IMMEDIATELY IN LANNETT COMPANY, INC. (LCI) AND COMMENCE DELISTING PROCEEDINGS PR Newswire
04.04.23 - PR Newswire
LANNETT SHARES UPDATE
LANNETT SHARES UPDATE PR Newswire
01.02.23 - PR Newswire
LANNETT REPORTS IMPROVED FISCAL 2023 SECOND QUARTER FINANCIAL RESULTS; RAISES FULL-YEAR GUIDANCE
LANNETT REPORTS IMPROVED FISCAL 2023 SECOND QUARTER FINANCIAL RESULTS; RAISES FULL-YEAR GUIDANCE PR Newswire
25.01.23 - PR Newswire
LANNETT ANNOUNCES 1 FOR 4 REVERSE STOCK SPLIT
LANNETT ANNOUNCES 1 FOR 4 REVERSE STOCK SPLIT PR Newswire
25.01.23 - PR Newswire
LANNETT TO REPORT FISCAL 2023 SECOND-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, FEBRUARY 1
LANNETT TO REPORT FISCAL 2023 SECOND-​QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, FEBRUARY 1 PR Newswire
04.01.23 - PR Newswire
LANNETT PROVIDES DEVELOPMENT UPDATE ON BIOSIMILAR INSULIN PRODUCTS
LANNETT PROVIDES DEVELOPMENT UPDATE ON BIOSIMILAR INSULIN PRODUCTS PR Newswire
07.11.22 - PR Newswire
LANNETT ANNOUNCES PATENT LICENSES FOR THE PEN INJECTOR DELIVERY DEVICE TO BE USED FOR ITS INSULIN GLARGINE AND INSULIN ASPART DEVELOPMENT PROGRAM
LANNETT ANNOUNCES PATENT LICENSES FOR THE PEN INJECTOR DELIVERY DEVICE TO BE USED FOR ITS INSULIN GLARGINE AND INSULIN ASPART DEVELOPMENT ...
02.11.22 - PR Newswire
LANNETT REPORTS BETTER THAN EXPECTED FINANCIAL RESULTS FOR FISCAL 2023 FIRST-QUARTER; REITERATES FULL-YEAR GUIDANCE
LANNETT REPORTS BETTER THAN EXPECTED FINANCIAL RESULTS FOR FISCAL 2023 FIRST-​QUARTER; REITERATES FULL-YEAR GUIDANCE PR Newswire
19.10.22 - PR Newswire
LANNETT ANNOUNCES SALE OF SEVERAL DISCONTINUED GENERIC DRUGS
LANNETT ANNOUNCES SALE OF SEVERAL DISCONTINUED GENERIC DRUGS PR Newswire
31.08.22 - PR Newswire
LANNETT ANNOUNCES SUBJECT DOSING COMPLETE FOR PIVOTAL CLINICAL TRIAL OF BIOSIMILAR INSULIN GLARGINE
LANNETT ANNOUNCES SUBJECT DOSING COMPLETE FOR PIVOTAL CLINICAL TRIAL OF BIOSIMILAR INSULIN GLARGINE PR Newswire
24.08.22 - PR Newswire
LANNETT REPORTS FISCAL 2022 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS
LANNETT REPORTS FISCAL 2022 FOURTH-​QUARTER, FULL-YEAR FINANCIAL RESULTS PR Newswire
19.08.22 - PR Newswire
LANNETT TO REPORT FISCAL 2022 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, AUGUST 24
LANNETT TO REPORT FISCAL 2022 FOURTH-​QUARTER, FULL-YEAR FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, AUGUST 24 PR Newswire
04.05.22 - PR Newswire
LANNETT REPORTS FISCAL 2022 THIRD-QUARTER FINANCIAL RESULTS
LANNETT REPORTS FISCAL 2022 THIRD-​QUARTER FINANCIAL RESULTS PR Newswire
27.04.22 - PR Newswire
LANNETT TO REPORT FISCAL 2022 THIRD-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, MAY 4
LANNETT TO REPORT FISCAL 2022 THIRD-​QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, MAY 4 PR Newswire
29.03.22 - PR Newswire
LANNETT INITIATES PIVOTAL CLINICAL TRIAL FOR BIOSIMILAR INSULIN GLARGINE
LANNETT INITIATES PIVOTAL CLINICAL TRIAL FOR BIOSIMILAR INSULIN GLARGINE PR Newswire
18.03.22 - PR Newswire
LANNETT ANNOUNCES RECEIPT OF NOTICE OF NON-COMPLIANCE FROM NYSE RELATED TO STOCK PRICE
LANNETT ANNOUNCES RECEIPT OF NOTICE OF NON-​COMPLIANCE FROM NYSE RELATED TO STOCK PRICE PR Newswire
04.03.22 - PR Newswire
LANNETT TO PRESENT AT THE 34th ANNUAL ROTH CONFERENCE ON MARCH 14
LANNETT TO PRESENT AT THE 34th ANNUAL ROTH CONFERENCE ON MARCH 14 --Company Announces Receipt of FDA Complete Response Letter (CRL) for Generic Advair ...
04.03.22 - PR Newswire
LANNETT ANNOUNCES RECEIPT OF NOTICE OF NON-COMPLIANCE FROM NYSE
LANNETT ANNOUNCES RECEIPT OF NOTICE OF NON-​COMPLIANCE FROM NYSE PR Newswire

Newssuche

Videos

18.04.24
Technical Trading: Gold mit weiterem Potenzial
Gold Long Typ: Turbo Open End WKN: UH4MU6 Hebel: 4,67 Laufzeit: OpenEnd Einstieg: Market ... Mehr »